国际肿瘤学杂志

国际肿瘤学杂志››2013,Vol. 40››Issue (2): 117-119.

• 综述 •上一篇下一篇

乳腺癌雌激素受体、孕激素受体和C-erbB-2在不同新辅助化疗前后的变化

史蓬亮, 张乃千, 张国强

  1. 150001哈尔滨医科大学附属第三医院乳腺外科一病区
  • 出版日期:2013-02-08发布日期:2013-01-25
  • 通讯作者:张国强，E-mail:6-fu@163.com E-mail:6-fu@163.com

Changes of estrogen receptor, progesterone receptor and C-erbB-2 expressions in different scheme pre- and post-neoadjuvant chemotherapies for breast cancer

SHI Peng-Liang, ZHANG Nai-Qian, ZHANG Guo-Qiang

  1. Department of Breast Surgery-Ward 1, Third Affiliated Hospital of Harbin Medical University, Harbin 150001 , China
  • Online:2013-02-08Published:2013-01-25
  • Contact:Corresponding author: ZHANG Guo-qiang, E-mail: 6-fu@163.com E-mail:6-fu@163.com

PDF

1394

被引次数

4

摘要：新辅助化疗在局部晚期乳腺癌的治疗中已被越来越广泛的应用。近年来研究表明，不同新辅助化疗前后肿瘤组织中雌激素受体(ER)、孕激素受体(PR)和人类表皮生长因子受体（C-erbB-2）的表达可能发生变化。在同时含有蒽环类及紫衫类化疗药物的新辅助化疗方案中改变较为明显，而在以蒽环类化疗药物为主的方案中无明显变化。

关键词:乳腺肿瘤,新辅助化疗,受体,雌激素,受体,孕酮,受体,erbB-2

Abstract:Neoadjuvant chemotherapy is widely used in the therapy of locally advanced breast cancer. In the recent studies, the expressions of ER, PR and C-erbB-2 in tumor may change in different scheme pre- and post-neoadjuvant chemotherapies for breast cancer. It is obviously changed in the neoadjuvant chemotherapy scheme of anthracyclines and paclitaxel/docetaxel, but hardly changed in anthracycline-based neoadjuvant chemotherapy scheme.

Key words:Breast neoplasms,Neoadjuvant chemotherapy,Receptors, estrogen,Receptors, progesterone,Receptors, erbB-2